Skip to main content
. 2023 May 25;34(8):1433–1444. doi: 10.1681/ASN.0000000000000161

Table 3.

Change from baseline in cardiac parameters according to the treatment group

Parameter Placebo Sodium Bicarbonate P Value
Ejection fraction, %
 Baseline 67.1 (60.3, 72.2) 68.1 (55.9, 73.0)
 End of study 65.3 (59.1, 69.4) 65.0 (57.8, 73.2)
 Change from baseline −1.9 (−5.3, 2.1) −0.7 (−6.7, 3.0) 0.41
Stroke volume, ml
 Baseline 71.3 (59.4, 82.3) 67.9 (60.5, 78.9)
 End of study 72.2 (58.6, 82.4) 68.9 (54.9, 87.4)
 Change from baseline −1.3 (−9.0, 10.3) −3.6 (−13.7, 5.7) 0.13
Cardiac output, L/min
 Baseline 4.7 (4.0, 5.9) 4.7 (4.1, 5.8)
 End of study 4.7 (4.2, 5.6) 4.5 (3.4, 5.7)
 Change from baseline −0.2 (−0.5, 0.8) −0.2 (−1.1, 0.4) 0.21
LVMI, g/m2
 Baseline 59.4 (51.4, 76.1) 57.4 (51.5, 67.9)
 End of study 67.6 (51.6, 78.3) 57.2 (53.1, 66.8)
 Change from baseline −1.6 (−9.7, 6.5) 2.7 (−4.1, 6.6) 0.51

The median and IQR at baseline and at the end of the study were calculated using all available data. The median (IQR) of the pre-post change were calculated for only those with data both before and after intervention. P values were calculated by the two-group t test in comparison of the pre-post change. LVMI, left ventricular mass index; IQR, interquartile range.